Circ_0000140 Alters miR-527/SLC7A11-Mediated Ferroptosis to Influence Oral Squamous Cell Carcinoma Cell Resistance to DDP

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Almangush A, Makitie AA, Triantafyllou A, et al. Staging and grading of oral squamous cell carcinoma: an update. Oral Oncol. 2020;107:104799. doi:10.1016/j.oraloncology.2020.104799
   PubMed Web of Science ®Google Scholar
• Loeffler TM, Lindemann J, Luckhaupt H, Rose KG, Hausamen TU. Chemotherapy of advanced and relapsed squamous cell cancer of the head and neck with split-dose cisplatinum (DDP), 5-fluorouracil (Fura) and leucovorin (CF). Adv Exp Med Biol. 1988;244:267–273.
   PubMedGoogle Scholar
• Guigay J, Auperin A, Fayette J, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, Phase 2 trial. Lancet Oncol. 2021;22(4):463–475. doi:10.1016/S1470-2045(20)30755-5
   PubMed Web of Science ®Google Scholar
• Han L, Li L, Wu G. Induction of ferroptosis by carnosic acid-mediated inactivation of Nrf2/HO-1 potentiates cisplatin responsiveness in OSCC cells. Mol Cell Probes. 2022;64:101821. doi:10.1016/j.mcp.2022.101821
   PubMed Web of Science ®Google Scholar
• Gao F, Han J, Wang Y, Jia L, Luo W, Zeng Y. Circ_0109291 promotes cisplatin resistance of oral squamous cell carcinoma by sponging miR-188-3p to Increase ABCB1 expression. Cancer Biother Radiopharm. 2022;37(4):233–245. doi:10.1089/cbr.2020.3928
   PubMed Web of Science ®Google Scholar
• Matsuura D, Valim TD, Kulcsar MAV, et al. Risk factors for salvage surgery failure in oral cavity squamous cell carcinoma. Laryngoscope. 2018;128(5):1113–1119. doi:10.1002/lary.26935
   PubMed Web of Science ®Google Scholar
• Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675–691. doi:10.1038/s41576-019-0158-7
   PubMed Web of Science ®Google Scholar
• Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol. 2020;21(8):475–490. doi:10.1038/s41580-020-0243-y
   PubMed Web of Science ®Google Scholar
• Lei M, Zheng G, Ning Q, Zheng J, Dong D. Translation and functional roles of circular RNAs in human cancer. Mol Cancer. 2020;19(1):30. doi:10.1186/s12943-020-1135-7
   PubMed Web of Science ®Google Scholar
• Paramasivam A. Circulating circular RNAs: novel potential biomarkers and therapeutic targets for oral cancer. Oral Oncol. 2022;134:106067. doi:10.1016/j.oraloncology.2022.106067
   PubMed Web of Science ®Google Scholar
• Peng QS, Cheng YN, Zhang WB, Fan H, Mao QH, Xu P. circRNA_0000140 suppresses oral squamous cell carcinoma growth and metastasis by targeting miR-31 to inhibit Hippo signaling pathway. Cell Death Dis. 2020;11(2):112. doi:10.1038/s41419-020-2273-y
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang M, Ren W, et al. Prognostic significance of CircRNAs expression in oral squamous cell carcinoma. Oral Dis. 2023;29(4):1439–1453. doi:10.1111/odi.14188
   PubMed Web of Science ®Google Scholar
• Huang L, Pei T, Wu G, Liu J, Pan W, Pan X. Circular RNAs as a diagnostic biomarker in oral squamous cell carcinoma: a meta-analysis. J Oral Maxillofac Surg. 2022;80(4):756–766. doi:10.1016/j.joms.2021.11.021
   PubMed Web of Science ®Google Scholar
• Liu J, Jiang X, Zou A, et al. circIGHG-induced epithelial-to-mesenchymal transition promotes oral squamous cell carcinoma progression via miR-142-5p/IGF2BP3 signaling. Cancer Res. 2021;81(2):344–355. doi:10.1158/0008-5472.CAN-20-0554
   PubMed Web of Science ®Google Scholar
• Peng L, Sang H, Wei S, et al. circCUL2 regulates gastric cancer malignant transformation and cisplatin resistance by modulating autophagy activation via miR-142-3p/ROCK2. Mol Cancer. 2020;19(1):156. doi:10.1186/s12943-020-01270-x
   PubMed Web of Science ®Google Scholar
• Cao Y, Xie X, Li M, Gao Y. CircHIPK2 Contributes to DDP resistance and malignant behaviors of DDP-resistant ovarian cancer cells both in vitro and in vivo through circHIPK2/miR-338-3p/CHTOP ceRNA pathway. Onco Targets Ther. 2021;14:3151–3165. doi:10.2147/OTT.S291823
   PubMed Web of Science ®Google Scholar
• Qiu F, Qiao B, Zhang N, et al. Blocking circ-SCMH1 (hsa_circ_0011946) suppresses acquired DDP resistance of oral squamous cell carcinoma (OSCC) cells both in vitro and in vivo by sponging miR-338-3p and regulating LIN28B. Cancer Cell Int. 2021;21(1):412. doi:10.1186/s12935-021-02110-8
   PubMed Web of Science ®Google Scholar
• Guo J, Su Y, Zhang M. Circ_0000140 restrains the proliferation, metastasis and glycolysis metabolism of oral squamous cell carcinoma through upregulating CDC73 via sponging miR-182-5p. Cancer Cell Int. 2020;20:407. doi:10.1186/s12935-020-01501-7
   PubMed Web of Science ®Google Scholar
• Conrad M, Pratt DA. The chemical basis of ferroptosis. Nat Chem Biol. 2019;15(12):1137–1147. doi:10.1038/s41589-019-0408-1
   PubMed Web of Science ®Google Scholar
• Hadian K, Stockwell BR. A roadmap to creating ferroptosis-based medicines. Nat Chem Biol. 2021;17(11):1113–1116. doi:10.1038/s41589-021-00853-z
   PubMed Web of Science ®Google Scholar
• Chen X, Li J, Kang R, Klionsky DJ, Tang D. Ferroptosis: machinery and regulation. Autophagy. 2021;17(9):2054–2081. doi:10.1080/15548627.2020.1810918
   PubMed Web of Science ®Google Scholar
• Xie H, Yao J, Wang Y, Ni B. Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis. Drug Deliv. 2022;29(1):1257–1271. doi:10.1080/10717544.2022.2057617
   PubMed Web of Science ®Google Scholar
• Yin J, Huang HY, Long Y, et al. circ_C20orf11 enhances DDP resistance by inhibiting miR-527/YWHAZ through the promotion of extracellular vesicle-mediated macrophage M2 polarization in ovarian cancer. Cancer Biol Ther. 2021;22(7–9):440–454. doi:10.1080/15384047.2021.1959792
   PubMed Web of Science ®Google Scholar
• Hong T, Lei G, Chen X, et al. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer. Redox Biol. 2021;42:101928. doi:10.1016/j.redox.2021.101928
   PubMed Web of Science ®Google Scholar
• Zhou HH, Chen X, Cai LY, et al. Erastin reverses ABCB1-mediated docetaxel resistance in ovarian cancer. Front Oncol. 2019;9:1398. doi:10.3389/fonc.2019.01398
   PubMed Web of Science ®Google Scholar